Priming of PRAME- and WT1-specific CD8(+) T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapy

Active immunotherapy may prevent the relapse of acute myeloid leukemia (AML) by inducing leukemia-specific T cells. Here, we investigated whether Wilms’ tumor 1 (WT1) and preferentially expressed antigen in melanoma (PRAME)-specific T cells could be induced upon the priming of healthy donor- and AML...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Ancker, Willemijn, Ruben, Jurjen M., Westers, Theresia M., Wulandari, Dewi, Bontkes, Hetty J., Hooijberg, Erik, Stam, Anita G.M., Santegoets, Saskia J.A.M., Ossenkoppele, Gert J., de Gruijl, Tanja, van de Loosdrecht, Arjan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654602/
https://www.ncbi.nlm.nih.gov/pubmed/23734332
http://dx.doi.org/10.4161/onci.23971

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654602/
https://www.ncbi.nlm.nih.gov/pubmed/23734332
http://dx.doi.org/10.4161/onci.23971

Ejemplares similares